Vitamin D receptor agonists: opportunities and challenges in drug discovery.
1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is an important hormone that regulates metabolism of calcium and phosphorus in small intestine, kidney, and bone, and its physiological action is expressed as ligand-dependent transcription activity mediated by vitamin D receptor (VDR). The VDR is found in various organs and cells including small intestine, kidney, and bone. In addition to the regulation of calcium metabolism, 1,25(OH)2D3 is involved in various biological reactions such as differentiation induction, antiproliferative effect, immunomodulatory effect, and regulation of cytokine and parathyroid hormone secretion. Thus, 1,25(OH)2D3 is expected to become a therapeutic drug for various related diseases. At present, a number of vitamin D derivatives are clinically applied to psoriasis, secondary hyperparathyroidism and osteoporosis but hypercalcemia and hypercalciuria are major concerns. Therefore, the current focus is directed toward new vitamin D derivatives with weak calcemic effects and a wide therapeutic window. In this summary, recent developments of new vitamin D derivatives for application in clinical treatment are described.
Takahashi
Tadakatsu
T
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd. 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. takahashitdk@chugai-pharm.co.jp
Morikawa
Kazumi
K
D015195:Drug Design; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D018167:Receptors, Calcitriol / Q000819:agonists*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*
D018167:Receptors, Calcitriol; D014807:Vitamin D